Related references
Note: Only part of the references are listed.MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
Michael Weller et al.
CLINICAL CANCER RESEARCH (2015)
Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression
Gunter Eisele et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal et al.
LANCET ONCOLOGY (2014)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp et al.
LANCET ONCOLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA
David A. Nathanson et al.
SCIENCE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Overcoming resistance to rapalogs in gliomas by combinatory therapies
Michal Grzmil et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2013)
Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial
Maria Teresa Solomon et al.
BMC CANCER (2013)
Glioblastoma cancer stem cells - From concept to clinical application
Barbara E. Stopschinski et al.
CANCER LETTERS (2013)
Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma
Panagiotis J. Vlachostergios et al.
CELL BIOLOGY AND TOXICOLOGY (2013)
Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
Arman Jahangiri et al.
CLINICAL CANCER RESEARCH (2013)
A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
David A. Reardon et al.
CLINICAL CANCER RESEARCH (2013)
The role of Gliadel wafers in the treatment of high-grade gliomas
Amade Bregy et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2013)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Hypoxia-inducible factor-1 as a therapeutic target in cancer
Ceen-Ming Tang et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2013)
One week on-one week off: efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center
Norbert Galldiks et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas
Vasilios Karavasilis et al.
JOURNAL OF NEUROLOGY (2013)
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme
David M. Peereboom et al.
NEURO-ONCOLOGY (2013)
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma
Bryan D. Choi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
Tracy T. Batchelor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma Hypotheses based on two prospective phase II trials
M. Balducci et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2013)
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
Emil Lou et al.
CANCER MEDICINE (2013)
Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited
Karl H. Plate et al.
ACTA NEUROPATHOLOGICA (2012)
A Safety Run-In and Randomized Phase 2 Study of Cilengitide Combined With Chemoradiation for Newly Diagnosed Glioblastoma (NABTT 0306)
L. Burt Nabors et al.
CANCER (2012)
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma
David A. Reardon et al.
CANCER (2012)
Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients
David A. Reardon et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Phase II Study of Short-Course Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Elderly Patients With Glioblastoma
Giuseppe Minniti et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Phase II Trial of Hypofractionated IMRT With Temozolomide for Patients With Newly Diagnosed Glioblastoma Multiforme
Krishna Reddy et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors
Ian Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery
Mark R. Gilbert et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
J. Drappatz et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study
Bret B. Friday et al.
NEURO-ONCOLOGY (2012)
Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma
Prakash Chinnaiyan et al.
NEURO-ONCOLOGY (2012)
A phase I/II trial of vandetanib for patients with recurrent malignant glioma
Teri N. Kreisl et al.
NEURO-ONCOLOGY (2012)
Polymer Wafers (Gliadel) in the Treatment of Malignant Glioma
Seema Nagpal
NEUROSURGERY CLINICS OF NORTH AMERICA (2012)
Targeting Glioma Stem Cells by Functional Inhibition of a Prosurvival OncomiR-138 in Malignant Gliomas
Xin Hui Derryn Chan et al.
CELL REPORTS (2012)
PHASE II EVALUATION OF GEFITINIB IN PATIENTS WITH NEWLY DIAGNOSED GRADE 4 ASTROCYTOMA: MAYO/NORTH CENTRAL CANCER TREATMENT GROUP STUDY N0074
Joon H. Uhm et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study
John F. de Groot et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Imatinib and docetaxel in combination can effectively inhibit glioma invasion in an in vitro 3D invasion assay
Paula Kinsella et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas
Manmeet S. Ahluwalia et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib-A Phase II Trial
Monika E. Hegi et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Inhibition of Sonic Hedgehog and Notch Pathways Enhances Sensitivity of CD133(+) Glioma Stem Cells to Temozolomide Therapy
Ilya V. Ulasov et al.
MOLECULAR MEDICINE (2011)
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
John H. Sampson et al.
NEURO-ONCOLOGY (2011)
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03
Fabio M. Iwamoto et al.
NEURO-ONCOLOGY (2011)
MicroRNA-34a: A Novel Tumor Suppressor in p53-mutant Glioma Cell Line U251
Shihai Luan et al.
ARCHIVES OF MEDICAL RESEARCH (2010)
Potential therapeutic implications of cancer stem cells in glioblastoma
Lin Cheng et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis
Tao Xu et al.
BMC CANCER (2010)
Exciting New Advances in Neuro-Oncology The Avenue to a Cure for Malignant Glioma
Erwin G. Van Meir et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation
Brian Thiessen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Carvedilol in glioma treatment alone and with imatinib in vitro
Mine Erguven et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2010)
An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines
Efstathia Giannopoulou et al.
INVESTIGATIONAL NEW DRUGS (2010)
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
Roger Stupp et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Vaccine provides new hope for patients with deadly brain cancer
[Anonymous]
FUTURE NEUROLOGY (2010)
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
James R. Perry et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma
Surasak Phuphanich et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Glioblastoma stem-like cells give rise to tumour endothelium
Rong Wang et al.
NATURE (2010)
MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients
O. Slaby et al.
NEOPLASMA (2010)
mTOR signaling in glioblastoma: lessons learned from bench to bedside
David Akhavan et al.
NEURO-ONCOLOGY (2010)
Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response
C. Hartmann et al.
ONCOGENE (2010)
Inhibition of Notch Signaling in Glioblastoma Targets Cancer Stem Cells via an Endothelial Cell Intermediate
Koos E. Hovinga et al.
STEM CELLS (2010)
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
John H. Sampson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
William Pao et al.
NATURE REVIEWS CANCER (2010)
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
B. Neyns et al.
ANNALS OF ONCOLOGY (2009)
A Vascular Normalization Index as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
A. Gregory Sorensen et al.
CANCER RESEARCH (2009)
MicroRNA-34a Inhibits Glioblastoma Growth by Targeting Multiple Oncogenes
Yunqing Li et al.
CANCER RESEARCH (2009)
Phase II Trial of Gliadel plus O6-Benzylguanine in Adults with Recurrent Glioblastoma Multiforme
Jennifer A. Quinn et al.
CLINICAL CANCER RESEARCH (2009)
Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy
John M. L. Ebos et al.
CLINICAL CANCER RESEARCH (2009)
Different Response of Human Glioma Tumor-initiating Cells to Epidermal Growth Factor Receptor Kinase Inhibitors
Fabrizio Griffero et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
The EGFRvIII variant in glioblastoma multiforme
Hui K. Gan et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2009)
Long-Term Survival of Patients With Glioblastoma Treated With Radiotherapy and Lomustine Plus Temozolomide
Martin Glas et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Evanthia Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells
Gary L. Gallia et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin
Melarkode S. Ramakrishnan et al.
MABS (2009)
FDA Drug Approval Summary: Bevacizumab (Avastin (R)) as Treatment of Recurrent Glioblastoma Multiforme
Martin H. Cohen et al.
ONCOLOGIST (2009)
Epidermal growth factor receptor and glioblastoma multiforme:: molecular basis for a new approach
Cristobal Belda-Iniesta et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2008)
Targeting the alpha 1 subunit of the sodium pump to combat glioblastoma cells
Florence Lefranc et al.
NEUROSURGERY (2008)
Histone deacetylase inhibitors: Overview and perspectives
Milos Dokmanovic et al.
MOLECULAR CANCER RESEARCH (2007)
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03
Ulrich Herrlinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis
B Kaur et al.
NEURO-ONCOLOGY (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Share Paper
